NexMed Says It Will Not File NDA for Nail Drug

NexMed, Inc. , a developer of products based on the NexACT drug delivery technology, today announced that based on First Interpretable Results of Phase III clinical studies for NM100060, a topical application ...

Comments

• Find It

• Recently Written

  • test post
  • Pfizer wins patent extension on cholesterol drug
  • More details released in case of pharmacy robber
  • If You Take Erectile Dysfunction Medications, Read This List
  • Health Canada Reminds Canadians of Important Safety Information For the Smoking-Cessation Aid Champix
  • Advaxis’ Phase II Clinical Trial “HOLD” Lifted
  • CMS Reports Lowest Rate of Overall Growth in National Health Spending Since 1998
  • HealthCentral Amasses Top Three Online Health Audience; Study Reveals More Consumers Turned to Internet for Health Info Than Their Physician Last Year
  • Dr. Paul Donohue
  • Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis

• Categories

  • News

• Monthly Archives

  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2009 Drug Injury News